Patents by Inventor Hanshi WONG

Hanshi WONG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Subgroup B recombinant human adenovirus vector, and methods for constructing and for using the same
    Patent number: 10294493
    Abstract: A subgroup B recombinant human adenovirus vector Ad11-5EP (SEQ ID NO: 1), which is constructed by a method including: substituting a 365 bp fragment containing an enhancer and a promoter of an upstream coding sequence of Ad5 E1A (SEQ ID NO: 2) for a corresponding region of a serotype Ad11 (SEQ ID NO: 3) of a subgroup B human adenovirus vector by homologous recombination to construct the subgroup B recombinant human adenovirus vector Ad11-5EP (SEQ ID NO: 1).
    Type: Grant
    Filed: February 25, 2018
    Date of Patent: May 21, 2019
    Assignee: BEIJING BIO-TARGETING THERAPEUTICS TECHNOLOGY INC.
    Inventors: Yaohe Wang, Guozhong Jiang, Hanshi Wong, Fengyu Cao, Nick Lemoine
  • SUBGROUP B RECOMBINANT HUMAN ADENOVIRUS VECTOR, AND METHODS FOR CONSTRUCTING AND FOR USING THE SAME
    Publication number: 20180187214
    Abstract: A subgroup B recombinant human adenovirus vector Ad11-5EP (SEQ ID NO: 1), which is constructed by a method including: substituting a 365 bp fragment containing an enhancer and a promoter of an upstream coding sequence of Ad5 E1A (SEQ ID NO: 2) for a corresponding region of a serotype Ad11 (SEQ ID NO: 3) of a subgroup B human adenovirus vector by homologous recombination to construct the subgroup B recombinant human adenovirus vector Ad11-5EP (SEQ ID NO: 1).
    Type: Application
    Filed: February 25, 2018
    Publication date: July 5, 2018
    Inventors: Yaohe WANG, Guozhong JIANG, Hanshi WONG, Fengyu CAO, Nick LEMOINE
  • Subgroup B recombinant human adenovirus vector, and methods for constructing and for using the same
    Patent number: 9932606
    Abstract: A method for reconstructing a replication-selective oncolytic adenovirus using a subgroup B recombinant human adenovirus vector Ad11-5EP. The method includes: 1) deleting E1A CR2 gene and/or anti-apoptotic gene E1B 21K that is necessary for viability of an adenovirus in normal cells but not necessary in tumor cells; 2) inserting a tumor-specific promoter to drive the expression of E1A gene; 3) re-directing a cellular tropism of Ad11-5EP according to receptors on a tumor cell surface; or 4) allowing adenovirus to selectively replicate in tumor cells.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: April 3, 2018
    Assignee: BEIJING BIO-TARGETING THERAPEUTICS TECHNOLOGY INC.
    Inventors: Yaohe Wang, Guozhong Jiang, Hanshi Wong, Fengyu Cao, Nick Lemoine
  • SUBGROUP B RECOMBINANT HUMAN ADENOVIRUS VECTOR, AND METHODS FOR CONSTRUCTING AND FOR USING THE SAME
    Publication number: 20160222413
    Abstract: A method for reconstructing a replication-selective oncolytic adenovirus using a subgroup B recombinant human adenovirus vector Ad11-5EP. The method includes: 1) deleting E1A CR2 gene and/or anti-apoptotic gene E1B 21K that is necessary for viability of an adenovirus in normal cells but not necessary in tumor cells; 2) inserting a tumor-specific promoter to drive the expression of E1A gene; 3) re-directing a cellular tropism of Ad11-5EP according to receptors on a tumor cell surface; or 4) allowing adenovirus to selectively replicate in tumor cells.
    Type: Application
    Filed: April 14, 2016
    Publication date: August 4, 2016
    Inventors: Yaohe WANG, Guozhong JIANG, Hanshi WONG, Fengyu CAO, Nick LEMOINE
  • Subgroup B recombinant human adenovirus vector, and methods for constructing and for using the same
    Patent number: 9315827
    Abstract: A method for constructing a subgroup B recombinant human adenovirus vector Ad11-5EP. The method includes substituting a 365 bp fragment including an enhancer and a promoter of an upstream coding sequence of Ad5 E1A for a corresponding region of a serotype Ad11 of the subgroup B human adenovirus vector by homologous recombination to construct the subgroup B recombinant human adenovirus vector Ad11-5EP. A subgroup B recombinant human adenovirus vector Ad11-5EP constructed by the method and the use thereof for treatment of tumors are also provided.
    Type: Grant
    Filed: November 29, 2013
    Date of Patent: April 19, 2016
    Assignee: Beijing Bio-Targeting Therapeutics Technology Inc.
    Inventors: Yaohe Wang, Guozhong Jiang, Hanshi Wong, Fengyu Cao, Nick Lemoine
  • SUBGROUP B RECOMBINANT HUMAN ADENOVIRUS VECTOR, AND METHODS FOR CONSTRUCTING AND FOR USING THE SAME
    Publication number: 20140088180
    Abstract: A method for constructing a subgroup B recombinant human adenovirus vector Ad11-5EP. The method includes substituting a 365 bp fragment including an enhancer and a promoter of an upstream coding sequence of Ad5 E1A for a corresponding region of a serotype Ad11 of the subgroup B human adenovirus vector by homologous recombination to construct the subgroup B recombinant human adenovirus vector Ad11-5EP. A subgroup B recombinant human adenovirus vector Ad11-5EP constructed by the method and the use thereof for treatment of tumors are also provided.
    Type: Application
    Filed: November 29, 2013
    Publication date: March 27, 2014
    Applicant: Beijing Bio-Targeting Therapeutics Technology Inc.
    Inventors: Yaohe WANG, Guozhong JIANG, Hanshi WONG, Fengyu CAO, Nick LEMOINE